Phase 3 ICONIC-ADVANCE Data
- Icotrokinra showed superior skin clearance versus placebo at Week 16 and versus deucravacitinib at Weeks 16 and 24.
- Adverse event rates were similar to placebo and numerically lower than with deucravacitinib through Week 24.
- No new safety signals were identified.
“These head-to-head data clearly demonstrate superior complete skin clearance rates for icotrokinra compared to deucravacitinib,” said Linda Stein Gold, M.D., Director of Dermatology Clinical Research at Henry Ford Health and ICONIC-ADVANCE study investigator. “This novel targeted oral peptide treatment has the potential to be an appealing new option for patients with moderate-to-severe plaque psoriasis.”
Long-Term ICONIC-LEAD Study Results
The ICONIC-LEAD study investigated icotrokinra in both adults and adolescents. At Week 52:
- 84% of adults who continued icotrokinra maintained a PASI 90 response, compared to 21% switched to placebo.
- 86% of adolescents treated with icotrokinra throughout achieved PASI 90, while 77% who switched from placebo also responded.
“The long-term data from ICONIC-LEAD continue to demonstrate the potential of icotrokinra to address the need for a novel targeted oral psoriasis treatment,” said Jennifer Soung, M.D., Director of Clinical Research at Southern California Dermatology and study investigator. “With many patients achieving clear or almost clear skin while maintaining a favourable safety profile through 52 weeks, icotrokinra could be a compelling new therapeutic option.”
Future Psoriasis Research
Johnson & Johnson has also initiated the ICONIC-ASCEND study, the first head-to-head trial to compare the efficacy of an oral pill (icotrokinra) with an injectable biologic (ustekinumab) in psoriasis.
